News

RNA Blockers Are Promising Alport Syndrome Therapy, Review Reports

Regulus Therapeutics and Sanofi-Genzyme are among companies working on Alport syndrome therapies that can block RNA molecules’ actions. RG-012 is a man-made version of naturally occurring oligonucleotides, or RNA molecules that help regulate gene activity. The synthetic version, called antisense oligonucleotides, binds to RNA, preventing it from functioning normally. But what are…

Australians Find Compound That Prevents the Protein Misfolding Seen in Alport Syndrome

Chemical compounds known as small chaperone molecules can prevent the protein-structure abnormalities associated with the most common type of Alport syndrome, Australian researchers report. This leads to normal production of the collagen protein that is missing in the disease. Gene mutations cause collagen to misfold. Naturally occurring chaperone molecules prevent misfolding,…